Clozaril Superior In Phase Two Of CATIE, But Side Effects Remain A Challenge

The superiority of Novartis' Clozaril over second-generation antipsychotics in the second phase of the National Institute of Mental Health's CATIE trial suggests the need to manage the serious side effects of clozapine therapy while expanding its use, study authors argue